Formulary Search
Search Results : Menopausal disorders (Gabapentin - Menopausal disorders)
Records returned : 39 (on 26 Jan 2026 at 05:56:13).
Return to search results for ' Menopausal disorders '.
Show Icon and Status Keys
Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Formulations :
- Capsules
Restrictions / Comments:
Important
Off-label use.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Preferred
Elleste Solo tablets - 1st line
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Patches
Restrictions / Comments:
Important
Estradiol patches 2nd line to tablets. No preferred patch recommendation has been made due to current stock shortages (Estraderm, Estradot, Evorel, FemSeven).
NOTE - discontinuation of the Progynova TS weekly patch by Dec 2025. FemSeven weekly patch remains available or twice-weekly Evoral / Estraderm patches.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Spray
Restrictions / Comments:
Important
Lenzetto spray. Caution with higher than licensed doses. Max supply of 20 containers per year to stay within licensed dose.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Gel
Restrictions / Comments:
Important
Oestrogel is the preferred gel option. Sandrena is an alternative option.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Progynova and Zumenon tablets NOT 1st line. Only prescribe where Elleste Solo tablets are unavailable.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Preferred
Femoston tablets - 1st line for women requiring sequential combined therapy.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Preferred
Femoston Conti - 1st line for women requiring continuous combined therapy.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Capsules
Restrictions / Comments:
Important
Preferred
Bijuve capsules - 1st line for women requiring continuous combined therapy.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Prescribe generically
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Patches
Restrictions / Comments:
Important
Femseven Conti patches - less preferred. Only use in the event of product shortages.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Kliofem tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Kliovance tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Elleste Duet Conti - 2nd line for women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line).
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Patches
Restrictions / Comments:
Important
Evorel Conti patches - preferred in women with risk factors for VTE or migraine. Otherwise use a 1st-line oral option.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Patches
Restrictions / Comments:
Important
Evorel Sequi patches 2nd-line. Preferred option in women with risk factors for VTE or migraine.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Elleste Duet tablets 2nd line. For women requiring sequential combined therapy but with poor cycle control on Femoston (1st-line).
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Novofem tablets - Only use if there are product shortages with Elleste Duet
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Trisequens tablets - consider changing to newer, 1st or 2nd line options.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intrauterine device (progestogen only)
Restrictions / Comments:
Important
Levonorgestrel recommended for replacement every 5 years (off-label use) as per BMS: https://thebms.org.uk/wp-content/uploads/2023/04/14-BMS-TfC-Progestogens-and-endometrial-protection-APR2023-A.pdf
- Mirena - licensed for endometrial protection but only for a duration of 4 years. Agreed to use for a duration of 5 years before replacement (off-label).
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
10mg tablets for adjunctive progestogen therapy
2nd line for endometrial protection in women who have abnormal bleeding on other HRT.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Off-label use.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Capsules
Restrictions / Comments:
Important
Off-label use.
Off-label use
Links :
Indication :
Status :
Formulations :
- Capsules
Restrictions / Comments:
Important
Preferred
Prescribe generically.
Micronised progesterone oral capsules.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Pessaries
Restrictions / Comments:
Important
Progesterone pessaries have not been agreed for use as endometrial protection.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Modified release tablets
Restrictions / Comments:
Important
Off-label use.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Recommend switching to a newer, lower risk formulation.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Modified release tablets
Restrictions / Comments:
Important
Premique Low Dose - no longer recommended. Switch to a newer, lower risk formulation.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Tridestra tablets - consider changing to a newer, 1st or 2nd line option.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Indivina tablets - consider changing to a newer, 1st or 2nd line option.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
This drug has not been assessed for inclusion on the formulary. Please contact your pharmacy team for advice.
Formulary Status :
Links :
Indication :
Status :
Restrictions / Comments:
Important
This drug has not been assessed for inclusion on the formulary. Please contact your pharmacy team for advice.
Formulary Status :
Links :
Indication :
Status :
Restrictions / Comments:
Formulary Status :
Links :